Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-928 in Advanced Solid Tumors
NCT05687682Phase 1Recruiting
- Sponsor
- AcadeMab Biomedical Inc.
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AM-928 in solid tumor (advanced stage) (7 arms), sponsored by AcadeMab Biomedical Inc. Primary endpoints: Maximum Tolerated Dose up to 29 days and Dose-Limiting Toxicity up to 29 days. Started Jul 2023; status: recruiting.
02
Drugs
AM-928
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05687682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687682.